BiotechTube
Corden BioChem

Corden BioChem

Tübingen, Germany· Est.
cordenbiochem.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

Corden BioChem Group is a major European CDMO with a 70-year legacy in fermentation and downstream processing, offering end-to-end contract manufacturing services for biotech products. The company operates a multi-site network with significant scale-up capacity, including a large-scale facility in Romania set to become operational in 2026. As a privately held entity within the International Chemical Investors Group (ICIG), it focuses on sustainable, biobased production across diverse non-pharmaceutical sectors.

Small MoleculesDrug Delivery

Technology Platform

Integrated microbial fermentation and downstream processing platform for scale-up and commercial manufacturing of biotechnological products. Expertise spans yeast, bacteria, fungi, and microalgae, with multi-site capabilities from lab-scale to over 3,000 m³ of fermentation capacity.

Funding History

2
Total raised:$10.5M
Series A$8M
Seed$2.5M

Opportunities

The global shift to a sustainable bioeconomy drives demand for fermentation-based alternatives to fossil-fuel-derived products.
The expansion of the Podari facility in 2026 will provide the largest fermentation capacity in Europe, positioning the company to capture large-volume contracts in food, feed, and industrial biotech.
Growing trend of outsourcing by biotech firms creates a robust market for CDMO services.

Risk Factors

Execution risk associated with the timely and on-budget commissioning of the new Podari, Romania production site.
Operational risks inherent in large-scale biological manufacturing, including process failures and contamination.
Competitive pressure in the CDMO landscape and potential client concentration or market segment volatility.

Competitive Landscape

Corden BioChem competes with other European fermentation CDMOs like Lonza, Evonik, and BASF's biotechnology divisions, as well as specialized players in food and feed ingredients. Its key competitive advantages are its claimed largest fermentation capacity in Europe, multi-organism expertise, and integrated scale-up pipeline. The private ownership by ICIG provides financial stability for long-term capacity investments.

More companies in Biologics / Biosimilars →More companies in Germany →